Spots Global Cancer Trial Database for acute myeloid leukemia with gene mutations
Every month we try and update this database with for acute myeloid leukemia with gene mutations cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant | NCT02723435 | Acute Myeloid L... Adult Acute Mye... | Midostaurin | 60 Years - | Stanford University | |
| CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | NCT04493164 | Acute Myeloid L... Myelodysplastic... Myeloproliferat... Recurrent Acute... Refractory Acut... | Ivosidenib Liposome-encaps... | 18 Years - | M.D. Anderson Cancer Center | |
| Expanded Treatment Protocol for Adults With FLT3-ITD Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) to Receive Quizartinib | NCT03746912 | Acute Myeloid L... | Quizartinib Dih... | 18 Years - | Daiichi Sankyo | |
| Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia | NCT01904136 | Accelerated Pha... Acute Myeloid L... Acute Myeloid L... Blast Phase Chr... de Novo Myelody... Myelodysplastic... Recurrent Acute... Recurrent Chron... Therapy-Related... | Allogeneic Hema... Bone Marrow Tra... Cyclophosphamid... Fludarabine Laboratory Biom... Melphalan Mycophenolate M... Natural Killer ... Peripheral Bloo... Tacrolimus Total-Body Irra... | 2 Years - 65 Years | M.D. Anderson Cancer Center | |
| Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine | NCT03588078 | Myelodysplastic... Acute Myeloid L... Myeloproliferat... Chronic Myelomo... | APR-246 Azacitidine | 18 Years - | Groupe Francophone des Myelodysplasies | |
| Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant | NCT02723435 | Acute Myeloid L... Adult Acute Mye... | Midostaurin | 60 Years - | Stanford University | |
| CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | NCT04493164 | Acute Myeloid L... Myelodysplastic... Myeloproliferat... Recurrent Acute... Refractory Acut... | Ivosidenib Liposome-encaps... | 18 Years - | M.D. Anderson Cancer Center | |
| Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia | NCT01904136 | Accelerated Pha... Acute Myeloid L... Acute Myeloid L... Blast Phase Chr... de Novo Myelody... Myelodysplastic... Recurrent Acute... Recurrent Chron... Therapy-Related... | Allogeneic Hema... Bone Marrow Tra... Cyclophosphamid... Fludarabine Laboratory Biom... Melphalan Mycophenolate M... Natural Killer ... Peripheral Bloo... Tacrolimus Total-Body Irra... | 2 Years - 65 Years | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
